Marinus Pharma Halts Development After Seizure Drug Fails Trial
Marinus said it will discontinue development of the drug, ganaxolone, and take further steps to reduce costs, including job cuts.
Written By : Farhat Nasim
Published On 2024-10-25 09:43 GMT | Update On 2024-10-25 09:43 GMT
Advertisement
Bengaluru: Marinus Pharmaceuticals said on Thursday it is exploring alternatives after the company's drug for treating seizures related to a rare brain disease failed to meet the main goal in a late-stage study.
The company's shares were down 65% to 56 cents in premarket trading.
Marinus said it will discontinue development of the drug, ganaxolone, and take further steps to reduce costs, including job cuts. It did not disclose the number of jobs that would be affected.
In June, an intravenous version of ganaxolone for a type of seizure known as refractory status epilepticus had also failed to meet one of the two key goals in a late-stage study.
Marinus was developing the oral version of the drug for the treatment of seizures associated with tuberous sclerosis complex in children and adults.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.